Seven Fleet Capital Management LP Takes Position in Enliven Therapeutics, Inc. $ELVN

Seven Fleet Capital Management LP purchased a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the fourth quarter, Holdings Channel.com reports. The fund purchased 11,688 shares of the company’s stock, valued at approximately $180,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ELVN. HighVista Strategies LLC raised its stake in shares of Enliven Therapeutics by 83.1% during the 3rd quarter. HighVista Strategies LLC now owns 259,135 shares of the company’s stock worth $5,304,000 after purchasing an additional 117,619 shares during the period. Tudor Investment Corp ET AL bought a new position in Enliven Therapeutics during the third quarter valued at about $334,000. Spruce Street Capital LP bought a new position in Enliven Therapeutics during the fourth quarter valued at about $6,870,000. Baker BROS. Advisors LP increased its holdings in Enliven Therapeutics by 136.3% during the fourth quarter. Baker BROS. Advisors LP now owns 271,406 shares of the company’s stock worth $4,180,000 after buying an additional 156,573 shares during the last quarter. Finally, Polar Capital Holdings Plc increased its holdings in Enliven Therapeutics by 13.5% during the fourth quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock worth $54,111,000 after buying an additional 418,673 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ELVN has been the topic of a number of research analyst reports. Guggenheim initiated coverage on shares of Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 target price on the stock. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. Mizuho upped their price objective on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Finally, The Goldman Sachs Group increased their price objective on Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $63.40.

Enliven Therapeutics Stock Up 0.5%

NASDAQ ELVN opened at $45.10 on Friday. The company has a market cap of $2.75 billion, a PE ratio of -27.01 and a beta of 0.29. Enliven Therapeutics, Inc. has a 52 week low of $14.78 and a 52 week high of $48.53. The firm’s 50-day simple moving average is $41.77 and its two-hundred day simple moving average is $31.41.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. As a group, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.71 EPS for the current year.

Insider Activity at Enliven Therapeutics

In other news, Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the completion of the transaction, the director directly owned 51,884 shares of the company’s stock, valued at $1,792,073.36. This trade represents a 16.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is owned by insiders.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.